Reuters logo
BRIEF-Arch Biopartners' lead anti-bacterial drug candidate to enter investigator-sponsored Phase I human trial
2017年4月13日 / 下午12点48分 / 7 个月前

BRIEF-Arch Biopartners' lead anti-bacterial drug candidate to enter investigator-sponsored Phase I human trial

April 13 (Reuters) - Arch Biopartners Inc:

* Arch Biopartners’ lead anti-bacterial drug candidate ab569 to enter investigator-sponsored Phase I human trial

* Arch Biopartners- Arch has initiated GMP manufacturing of AB569 drug product that is required for trial Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below